Kenvue Inc. (NYSE:KVUE) Stock Holdings Boosted by Brooklyn Investment Group

Brooklyn Investment Group boosted its position in Kenvue Inc. (NYSE:KVUE) by 37.3% during the 4th quarter, HoldingsChannel reports. The firm owned 4,243 shares of the company’s stock after buying an additional 1,152 shares during the quarter. Brooklyn Investment Group’s holdings in Kenvue were worth $91,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Riverview Trust Co bought a new stake in shares of Kenvue during the third quarter valued at approximately $30,000. Fortitude Family Office LLC increased its position in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares during the period. Ashton Thomas Securities LLC bought a new stake in Kenvue during the 3rd quarter valued at $35,000. Versant Capital Management Inc boosted its position in Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after acquiring an additional 1,441 shares during the period. Finally, Deseret Mutual Benefit Administrators grew its stake in shares of Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after purchasing an additional 651 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. UBS Group cut their price objective on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday. JPMorgan Chase & Co. upped their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Barclays lowered their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. Finally, Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $23.08.

Kenvue Stock Down 0.4 %

Shares of Kenvue stock opened at $21.11 on Monday. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The firm has a market capitalization of $40.46 billion, a PE ratio of 38.37, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock’s fifty day moving average is $22.42 and its 200-day moving average is $21.71.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same period in the prior year, the firm earned $0.31 earnings per share. The business’s quarterly revenue was down .4% on a year-over-year basis. Equities analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.89%. Kenvue’s dividend payout ratio is 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.